Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03438227
Other study ID # 1809251633
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 15, 2018
Est. completion date December 31, 2019

Study information

Verified date August 2020
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. While treatment of iron-deficiency anemia with iron supplementation is recommended, treatment strategies remain controversial: the American College of Obstetrics and Gynecology recommends oral iron supplementation with parental iron reserved for the rare patient who cannot tolerate or will not take oral iron, while UK professional organizations recommend a more liberal use of parenteral iron. The reason for these disparate recommendations is that few high-quality studies comparing oral to parenteral iron have been conducted in developed countries, and the potential impact of parental iron treatment on obstetric and perinatal outcomes remains unclear. We propose the first randomized-controlled trial in the United States describing the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron.


Description:

Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. In the U.S., anemia affects nearly 20% of pregnancies and the majority is iron-deficiency anemia. Therefore, treatment of iron-deficiency anemia with iron supplementation is recommended.1 However, there is controversy about the treatment strategies.

The American College of Obstetrics and Gynecology recommends oral iron supplementation for iron-deficiency anemia in pregnancy, with parental iron reserved only for the "rare patient who cannot tolerate or will not take oral iron" (1) Conversely, guidelines from the U.K. are more liberal on the use of parental iron for the treatment of iron-deficiency anemia in pregnancy (2). Both treatment guidelines are based on limited data regarding the risks and benefits of parental iron for treatment of iron-deficiency anemia in pregnancy. The majority of randomized trials were conducted in developing country settings. In fact, few high-quality studies have been conducted in developed countries, and none has been conducted in the U.S. Moreover, there is limited data from prior studies on the impact of parental iron treatment on perinatal outcomes. The most recent Cochrane review including mostly from trials conducted in low-income countries found that, although parenteral iron improved hemoglobin levels and iron stores than the oral route, no clinical outcomes were assessed and there were insufficient data on adverse effects (3). The authors concluded that "large, good quality trials, assessing clinical outcomes including adverse effects … are required" (3).

This randomized controlled trial aims to assess the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron. We hypothesize that treating iron-deficiency anemia with parental iron is associated with improved maternal and neonatal outcomes compared with a protocol based on oral iron. To increase generalizability of the findings, we will use broad inclusion criteria and analyze data using the intention-to-treat principle.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Iron-deficiency anemia (serum ferritin <30 micrograms, normal hemoglobin electrophoresis, and hemoglobin <10 mg/dL), planned delivery at Barnes-Jewish Hospital

Exclusion Criteria:

- Non-iron-deficiency anemia, multiple gestation, prenatally diagnosed major fetal anomalies, known aneuploidy, planned delivery at other hospital, inability to obtain consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Iron dextran
Single intravenous infusion of iron dextran 1000mg.
Ferrous sulfate 325mg
Oral iron supplementation with ferrous sulfate 325mg one to three times daily

Locations

Country Name City State
United States Indiana University School of Medicine Indianapolis Indiana
United States Center for Outpatient Health, Washington University in St. Louis Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

References & Publications (3)

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: anemia in pregnancy. Obstet Gynecol. 2008 Jul;112(1):201-7. doi: 10.1097/AOG.0b013e3181809c0d. Erratum in: Obstet Gynecol. 2020 Jan;135(1):222. — View Citation

Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C; British Committee for Standards in Haematology. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012 Mar;156(5):588-600. Erratum in: Br J Haematol. 2012 Aug;158(4):559. — View Citation

Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD003094. doi: 10.1002/14651858.CD003094.pub3. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal outcome: hemoglobin on admission to inpatient obstetrics unit for delivery of infant Hemoglobin On admission to inpatient obstetrics unit for delivery of infant
Secondary Incidence of Medication Adverse events [Safety and Tolerability] Research assistants will contact all patients receiving iron infusions 2 days after their infusion to assess for symptoms via a telephone questionnaire. 2 days after after iron infusion
Secondary Maternal outcome: hemoglobin on postpartum day #1 Hemoglobin On day after participant delivered her infant (i.e. postpartum day #1)
Secondary Maternal outcome: incidence of blood transfusion Participant receiving transfusion of packed red blood cells during admission for delivery of infant obtained via medical chart review. During inpatient admission for delivery of neonate
Secondary Maternal outcome: mode of delivery Whether infant was delivered vaginally or via cesarean section Once, at infant delivery
Secondary Neonatal outcomes: gestational age at delivery Gestational age at delivery Once, at infant delivery
Secondary Neonatal outcomes: birth weight Infant birth weight Obtained once, at infant delivery
Secondary Neonatal outcomes: umblical cord gases Umbilical cord gases Drawn once from umbilical cord segment at birth
Secondary Neonatal outcomes: APGAR scores APGAR scores. The APGAR score measures the physical condition of a newborn infant on a scale from 0 to 10 by adding points (2, 1, or 0) for heart rate, respiratory effort, muscle tone, response to stimulation, and skin color. Obtained at 1 minute and 5 minutes of life
Secondary Neonatal outcomes: neonatal hemoglobin Neonatal hemoglobin Drawn once from umbilical cord segment at birth
Secondary Neonatal outcomes: neonatal morbidity composite Neonatal morbidity composite, defined by the occurrence of one or more of the following neonatal morbidities: neonatal seizures, intraventricular hemorrhage, hypoxic-ischemic encephalopathy, neonatal hypothermic therapy, sepsis, respiratory distress syndrome, hyperbilirubinemia requiring photo therapy, birth injury, or meconium aspiration syndrome, NICU admission At birth
See also
  Status Clinical Trial Phase
Completed NCT03456258 - Lactoferrin Versus Ferrous Sulphate for the Treatment of Iron Deficiency Anemia During Pregnancy N/A
Not yet recruiting NCT04074707 - Defining a Dosing Regimen With Maximal Absorption for Oral Iron Supplementation During Pregnancy N/A
Completed NCT03481790 - Lactoferrin Versus Ferrous Sulphate for Treatment of Iron Deficiency Anaemia During Pregnancy Phase 2
Terminated NCT04594070 - Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy Phase 4
Completed NCT03706638 - Daily vs Intermittent Iron Therapy in Pregnancy N/A
Recruiting NCT06366698 - Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia Phase 3
Not yet recruiting NCT03484845 - Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy Phase 1/Phase 2
Completed NCT03961074 - Iron Deficiency Anemia Among Chinese Pregnant Women: a Multi-center Prospective Cohort Study
Recruiting NCT05804071 - Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in Pregnancy Phase 4
Recruiting NCT04008147 - Hepcidin and Glucose Metabolism N/A
Completed NCT03188445 - Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy. Phase 4
Completed NCT05157828 - Iron Deficiency Anaemia in Pregnant Patients Presenting for Antenatal Care
Active, not recruiting NCT05545527 - Neuroimaging Ancillary Study
Completed NCT05725278 - Impact Evaluation of Triggerise's Tiko Platform N/A
Completed NCT03378791 - Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women Phase 3
Completed NCT02005588 - Treatment of Iron Deficiency Anemia With Pregnancy Phase 0
Completed NCT03657433 - Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy Phase 3
Completed NCT04976179 - Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON) Phase 3
Available NCT05151679 - Chelated Oral Iron Versus Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia Late in Pregnancy